GenSight Biologics SA (G49N) Financial Statements
GenSight Biologics SA Financial Overview
GenSight Biologics SA's market cap is currently $18.98M. The company's EPS TTM is $-0.07; its P/E ratio is -1.06; GenSight Biologics SA has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 1.00K | $ 2.63M | $ 1.27M | $ 2.58M | $ 5.28M |
| Gross Profit | $ 1.00K | $ 2.63M | $ 3.00M | $ 2.58M | $ 5.28M |
| Operating Income | $ -11.71M | $ -15.81M | $ -29.70M | $ -27.84M | $ -28.13M |
| EBITDA | $ -11.24M | $ -14.76M | $ -21.73M | $ -26.77M | $ -25.52M |
| Net Income | $ -12.04M | $ -14.00M | $ -26.22M | $ -27.62M | $ -28.62M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 2.42M | $ 2.46M | $ 2.13M | $ 10.61M | $ 44.29M |
| Total Assets | $ 8.26M | $ 10.76M | $ 9.13M | $ 25.94M | $ 56.65M |
| Total Debt | $ 12.86M | $ 19.11M | $ 23.54M | $ 12.65M | $ 12.57M |
| Net Debt | $ 10.45M | $ 16.65M | $ 21.40M | $ 2.04M | $ -31.72M |
| Total Liabilities | $ 33.20M | $ 37.68M | $ 39.83M | $ 41.22M | $ 40.66M |
| Stockholders' Equity | $ -24.94M | $ -26.92M | $ -30.67M | $ -15.28M | $ 15.99M |
| Cash Flow | |||||
| Free Cash Flow | $ -9.38M | $ -12.94M | $ -24.67M | $ -34.01M | $ -17.17M |
| Operating Cash Flow | $ -9.38M | $ -12.94M | $ -24.66M | $ -33.75M | $ -17.14M |
| Investing Cash Flow | $ 180.00K | $ 17.00K | $ 209.00K | $ 172.00K | $ -16.00K |
| Financing Cash Flow | $ 9.14M | $ 13.54M | $ 15.86M | $ 95.00K | $ 23.74M |
Currency in EUR